PIV5-vectored OspA-based vaccine provides long-term protection against B. burgdorferi infection in mice
Feb. 21, 2024
Immuno Technologies Inc. and affiliated organizations have published preclinical data on a novel parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease.